Search Results - "Kotecha, R.S."

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol by Stutterheim, J., de Lorenzo, P., van der Sluis, I.M., Alten, J., Ancliffe, P., Attarbaschi, A., Aversa, L., Boer, J.M., Biondi, A., Brethon, B., Diaz, P., Cazzaniga, G., Escherich, G., Ferster, A., Kotecha, R.S., Lausen, B., Leung, Alex WK, Locatelli, F., Silverman, L., Stary, J., Szczepanski, T., van der Velden, V.H.J., Vora, A., Zuna, J., Schrappe, M., Valsecchi, M.G., Pieters, R.

“…The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior…”
Get full text

Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia by Mateos, M.K., Trahair, T.N., Mayoh, C., Barbaro, P.M., Sutton, R., Revesz, T., Barbaric, D., Giles, J.E., Alvaro, F., Mechinaud, F., Catchpoole, D., Kotecha, R.S., Dalla-Pozza, L., Quinn, M.C.J., MacGregor, S., Chenevix-Trench, G., Marshall, G.M.

“…Symptomatic venous thromboembolism (VTE) is an unpredictable and life-threatening toxicity, which occurs early in childhood acute lymphoblastic leukemia (ALL)…”
Get full text